ѻý

<ѻý class="page-title">Meeting Coverage

MBCC

<ѻý class="page-description">Miami Breast Cancer Conference
Focus on Optimizing Use of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

Choice of agent, post-progression treatment, and resistance mechanisms top unanswered questions

MBCC over a photo of the Fontainebleau Miami Beach in Miami, Florida.
<ѻý class="section_title">Latest MBCC Meeting Coverage
Understanding of HER2-Low Breast Cancer Continues to Evolve

New breast cancer subtype proves challenging to define molecularly, pathologically, clinically

March 7, 2023
Cases of Breast Implant-Associated Lymphoma Continue to Accumulate

More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge

March 6, 2023
'Our Goal Is Not to Omit Radiation Therapy' in Breast Cancer

Honing indications for de-escalation of treatment intensity and, yes, selective omission of RT

March 6, 2023
Antibody-Drug Conjugates Take Breast Cancer Field by Storm

Established role in metastatic disease, may eventually replace chemotherapy

March 4, 2023
Another Casualty of COVID-19: Evidence-Based Medicine

Physician laments decline in research quality, critical appraisal during pandemic

March 9, 2022
Androgen Receptor Agonist Active in Resistant ER+ Breast Cancer

Also: Combination targets uncommon form of advanced HER2-mutant disease

March 9, 2022
More Options for Precision Medicine in Metastatic Triple-Negative Breast Cancer

Moving beyond chemotherapy to immunotherapy, PARP inhibitors, ADCs, combinations

March 8, 2022
Chipping Away at the Dogma of Axillary Dissection in Breast Cancer

Ongoing trials could help some women avoid even less-invasive sentinel lymph node biopsy

March 7, 2022
Clinical Picture Brightens for HER2+ Breast Cancer With Brain Metastases

New therapies breach blood-brain barrier to improve response, survival

March 7, 2022
Honing the Indications for Adjuvant CDK4/6 Inhibition in Breast Cancer

Defining high risk, considering role of Ki-67, BRCA mutations

March 5, 2022
Beyond CDK4/6 Inhibitors for HR-Positive Breast Cancer

Switching drugs, taking aim at different targets under investigation

March 11, 2020